Industry Information

Update October 30, 2021

Qin Hao Pharmaceutical's new SHP2 inhibitor clinical trial application was approved in the U.S.

Recently, Qinhao Pharmaceutical announced that its strategic partner Huya Bio-International has submitted a new drug clinical trial application for GH21 to the U.S. Food and Drug Administration...

Update October 27, 2021

Hengrui PD-1 monoclonal antibody combined with Famitinib for the treatment of non-small cell lung cancer phase III clinical approval

On October 26, Hengrui Pharmaceuticals announced that it had obtained the "Notice of Drug Clinical Trial Approval" approved and issued by the National Medical Products Administration, approving the...

Update October 26, 2021

The first in the world! Heji Pharmaceuticals ITK Inhibitor Approved for Clinical

On October 26, 2021, Heji Pharmaceuticals announced that the world’s first ITK inhibitor to enter the clinical development stage, the clinical trial application of CPI-818 for oral use has obtained...

Update October 23, 2021

Simcere's breast cancer innovative drug SIM0270 (SCR-6852) clinical trial application accepted

On October 21, 2021, the clinical trial application for the innovative breast cancer drug SIM0270 (SCR-6852) independently developed by Simcere was accepted by the Center for Drug Evaluation (CDE) of...

Update October 21, 2021

Benefiting from centralized procurement and relying on a single product, Huiyu Pharmaceutical will soon be listed on the Sci-tech Innovation Board. What is the potential?

On October 18, Huiyu Pharmaceutical issued a prospectus for listing on the Science and Technology Innovation Board. Its initial public offering of shares began on October 12 and ended on October 14....

Update October 18, 2021

Ganli Pharmaceutical Insulin Glargine (GL-GLA) completed overseas Phase III clinical study

Beijing, China/Bridgewater, New Jersey, USA, October 14, 2021-Ganli Pharmaceutical Co., Ltd. (hereinafter referred to as Ganli Pharmaceutical, stock code: 603087.SH) announced that it has...

Update October 15, 2021

ECTRIMS Conference丨Roche, Sanofi, Bojian and many other pharmaceutical companies announce the latest clinical data of multiple sclerosis drugs

Multiple sclerosis (MS) is a disabling disease of the central nervous system that affects more than one million Americans. The disease is also one of the hot areas actively developed by global...

Update October 14, 2021

Galenwolizumab is clinically active in the treatment of hepatitis B IIa

Hangzhou, China and Shaoxing, October 12, 2021--Gallite Pharmaceutical Co., Ltd. (Hong Kong Stock Exchange code: 1672) today announced its subcutaneous injection of PD-L1 antibody ASC22 (Envolimab)...

Update October 12, 2021

With a compound annual growth rate of 12.57%, who will be the dominant player in the G-CSF market?

On October 8, Yifan Pharmaceutical issued an announcement that the long-acting G-CSF needle F-627 (Aibeguestine α) of Yiyi Biotech was issued by the European Medicines Agency (EMA) on September 30....

Update October 11, 2021

Microchip's Diabetes Class 1 new drug "siglita sodium" will be approved soon!

Yaozhi data shows that the new drug listing application of Siglita Sodium, a new class 1 drug for the treatment of diabetes by Microchip Biotechnology, has entered "under approval" and is expected to...